22 264

Cited 14 times in

A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.

Authors
Lee, JJ; Kim, SY; Chung, HC; Lee, KH; Song, HS; Kang, WK; Hong, YS; Choi, IS; Lee, YY; Woo, IS; Choi, JH
Citation
Cancer chemotherapy and pharmacology, 63(6):1083-1090, 2009
Journal Title
Cancer chemotherapy and pharmacology
ISSN
0344-57041432-0843
Abstract
PURPOSE: This study was conducted to evaluate the safety and efficacy of S-1 and paclitaxel combination therapy for patients with advanced gastric cancer. METHODS: Eligible patients had previously untreated advanced or relapsed gastric cancer with measurable lesion(s) and an ECOG PS of 0-2. Treatment consisted of S-1 35 mg/m(2) p.o. b.i.d. on days 1-14 followed by a 7-day off plus paclitaxel 70 mg/m(2) i.v. on days 1 and 8 of a 21-day cycle. RESULTS: Fifty-six patients (M/F = 37/19) were enrolled. The median age was 59 years. The median number of cycles administered was six (range 1-18). Out of the 53 patients evaluated, there was 1 (1.9%) CR, 20 (37.7%) confirmed PRs, 5 (9.4%) unconfirmed PRs, 21 (39.6%) SDs, and 6 (11.3%) PDs. The objective tumor response was 39.6%. The median time to progression was 29 weeks. The median survival was 51 weeks. All 56 patients were assessed for treatment safety. The treatment was well tolerated with grade 3/4 neutropenia in 20%/13%, grade 3 febrile neutropenia in 7%, grade 2/3 diarrhea in 9%/4%, vomiting in 11%/0%, stomatitis in 4%/4%, and neuropathy in 4%/0% of patients. CONCLUSIONS: S-1 and paclitaxel combination treatment is an effective regimen with a favorable toxicity profile in patients with advanced gastric cancer.
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy Protocols/administration & dosageAntineoplastic Combined Chemotherapy Protocols/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic use*Drug Administration ScheduleDrug CombinationsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, Local/drug therapy*Neoplasm Recurrence, Local/mortalityNeoplasm Recurrence, Local/pathologyOxonic Acid/administration & dosageOxonic Acid/adverse effectsOxonic Acid/therapeutic usePaclitaxel/administration & dosagePaclitaxel/adverse effectsPaclitaxel/therapeutic useProspective StudiesStomach Neoplasms/drug therapy*Stomach Neoplasms/mortalityStomach Neoplasms/pathologyTegafur/administration & dosageTegafur/adverse effectsTegafur/therapeutic use
DOI
10.1007/s00280-008-0818-3
PMID
18813927
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
최진혁
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse